Acadia Pharmaceuticals
ACAD
247 hedge funds and large institutions have $3.46B invested in Acadia Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 69 increasing their positions, 94 reducing their positions, and 29 closing their positions.
438% more call options, than puts
Call options by funds: $87.9M | Put options by funds: $16.3M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
44% more capital invested
Capital invested by funds: $2.41B → $3.46B (+$1.05B)
4% more funds holding
Funds holding: 237 → 247 (+10)
2.02% more ownership
Funds ownership: 90.16% → 92.19% (+2%)
27% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$61.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$31.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$15.1M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$14.4M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.9M |
| 2 |
D.E. Shaw & Co
New York
|
-$21M |
| 3 |
State Street
Boston,
Massachusetts
|
-$18.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$8.93M |
ACAD Hedge Fund Activity: Q4 2021 in Review
247 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2021, worth a combined $3.46B — up 44% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ACAD positions and 29 closed out — a net gain of 13 holders — while 69 added to existing stakes and 94 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $61.6M. The largest seller was Fidelity Investments, cutting an estimated $40.9M.
- 247 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2021, up from 237 in Q3 2021.
- Funds reported $3.46B of Acadia Pharmaceuticals stock for Q4 2021, up 44% quarter-over-quarter.
- 42 funds opened new Acadia Pharmaceuticals positions in Q4 2021 and 29 closed out, a net change of +13 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2021 was EcoR1 Capital, an estimated $61.6M added.
- The largest Acadia Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $40.9M sold.
Based on aggregated 13F filings for Q4 2021.